Introduction：Basic information about CAS 745013-59-6|Tremelimumab, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Tremelimumab |
|---|
| CAS Number | 745013-59-6 | Molecular Weight | / |
|---|
| Density | / | Boiling Point | / |
|---|
| Molecular Formula | / | Melting Point | / |
|---|
| MSDS | / | Flash Point | / |
|---|
Names
| Name | Tremelimumab |
|---|
| Synonym | More Synonyms |
|---|
Tremelimumab BiologicalActivity
| Description | Tremelimumab (Ticilimumab) is a fully humanized monoclonal antibody specific for cytotoxic T-lymphocyte antigen-4 (CTLA-4) and can be used for metastatic melanoma research[1]. |
|---|
| Related Catalog | Research Areas >>CancerSignaling Pathways >>Others >>OthersResearch Areas >>Inflammation/Immunology |
|---|
| In Vitro | Tremelimumab (Ticilimumab) has a higher affinity for CTLA-4-Ig than for CD28-Ig and that the antibody is specific for cynomolgus monkeys and humans[1]. Tremelimumab does not bind to human leukocyte FcγR and does not trigger the release of cytokines avoiding the cytokine release syndrome, but increases the IL-2 production upon stimulation with the staphylococcal enterotoxin A in a concentration-dependent manner[1]. Tremelimumab enhances the IL-2 production in T-cells[1]. |
|---|
| References | [1]. Comin-Anduix B, et al. Tremelimumab: research and clinical development. Onco Targets Ther. 2016 Mar 23;9:1767-76. |
|---|
Chemical & Physical Properties
Synonyms
